Get started
Author

Yafei Wang

Mutations or copy number losses of CD58 and TP53 genes in diffuse large B cell lymphoma are independent unfavorable prognostic factors
2016 · Yang Cao, Tao Zhu, et al. · Oncotarget · 52
PDF
Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Chinese Patients with Relapsed or Refractory Multiple Myeloma: Phase 3 LEPUS (MMY3009) Study
2021 · Jin Lu, Weijun Fu, et al. · Clinical Lymphoma Myeloma & Leukemia · 37
MicroRNA-21 and multiple myeloma: small molecule and big function
2014 · Jing Ma, Su Liu, et al. · Medical Oncology · 22
Radiomics in cone-beam breast CT for the prediction of axillary lymph node metastasis in breast cancer: a multi-center multi-device study
2023 · Yueqiang Zhu, Yue Ma, et al. · European Radiology · 19
PDF
CXCL10 Recruitment of γδ T Cells into the Hypoxic Bone Marrow Environment Leads to IL17 Expression and Multiple Myeloma Progression
2023 · Jingya Wang, Ziyi Peng, et al. · Cancer Immunology Research · 19
Comparison of background parenchymal enhancement (BPE) on contrast-enhanced cone-beam breast CT (CE-CBBCT) and breast MRI
2022 · Yue Ma, Aidi Liu, et al. · European Radiology · 17
Daratumumab, Bortezomib, and Dexamethasone versus Bortezomib and Dexamethasone in Chinese Patients With Relapsed or Refractory Multiple Myeloma: Updated Analysis of LEPUS
2022 · Weijun Fu, Wei Li, et al. · Clinical Lymphoma Myeloma & Leukemia · 16
RAS/RAF mutations in tumor samples and cell-free DNA from plasma and bone marrow aspirates in multiple myeloma patients
2020 · Qian Li, Helen J Huang, et al. · Journal of Cancer · 14
PDF
Hypermethylation of SHP-1 promoter in patient with high-risk myelodysplastic syndrome and it predicts poor prognosis
2012 · Yizhuo Zhang, Dandan Zhao, et al. · Medical Oncology · 14
Further stratification of patients with multiple myeloma by International Staging System in combination with ratio of serum free κ to λ light chains
2012 · Yan Xu, Weiwei Sui, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 13
Efficacy, safety, and pharmacokinetics of teclistamab in Chinese patients with relapsed/refractory multiple myeloma from the China cohort of MajesTEC‐1
2024 · Zhen Cai, Zhongjun Xia, et al. · Cancer · 12
Immunophenotypic Landscape and Prognosis-Related mRNA Signature in Diffuse Large B Cell Lymphoma
2022 · Yanan Jiang, Huimeng Sun, et al. · Frontiers in Genetics · 11
PDF
Correlation Between Uptake of 18 F-FDG During PET/CT and Ki-67 Expression in Patients Newly Diagnosed With Multiple Myeloma Having Extramedullary Involvement
2019 · Qian Li, Jing Ma, et al. · Technology in Cancer Research & Treatment · 10
Daratumumab, bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone alone in transplant-ineligible Asian patients with newly diagnosed multiple myeloma: final analysis of the phase 3 OCTANS Study
2024 · Weijun Fu, Soo-Mee Bang, et al. · Annals of Hematology · 9
PDF
Efficacy and safety of pomalidomide and low-dose dexamethasone in Chinese patients with relapsed or refractory multiple myeloma: a multicenter, prospective, single-arm, phase 2 trial
2022 · Wei-Jun Fu, Ya-Fei Wang, et al. · BMC Cancer · 9
PDF
Studies on Budd-chiari syndrome complicated with hepatocellular carcinoma: most patients without inferior vena cava obstruction.
2015 · Xiaowei Dang, Luhao Li, et al. · PubMed · 9
A lower ALC/AMC ratio is associated with poor prognosis of peripheral T-cell lymphoma-not otherwise specified
2018 · Qian Li, Shuang Gao, et al. · Leukemia Research · 8
Multiple myeloma with dural mater involvement
2019 · Su Liu, Xubin Li, et al. · OncoTargets and Therapy · 7
PDF
ALK-positive anaplastic large cell lymphoma with prominent bone involvement in a 13-year-old boy
2016 · Chen Tian, Yong Yu, et al. · OncoTargets and Therapy · 6
PDF
Mezigdomide, carfilzomib, and dexamethasone versus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma (SUCCESSOR-2): a phase 3, open-label, randomised controlled trial
2026 · Meletios A Dimopoulos, Fredrik Schjesvold, et al. · The Lancet · 5
PDF
STING signaling pathway: An oasis in the glioblastoma immune desert
2026 · Yafei Wang, Weichen Duan, et al. · Theranostics · 5
PDF
Myeloid neoplasms post cytotoxic therapy: epidemiology, pathogenesis outcomes, prognostic factors, and treatment options
2024 · Jing Ma, Yafei Wang · Annals of Medicine · 5
PDF
DUT enhances drug resistance to proteasome inhibitors via promoting mitochondrial function in multiple myeloma
2022 · Yafei Wang, Shuang Gao, et al. · Carcinogenesis · 5
PDF
Health-related quality of life with daratumumab, bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone alone in transplant-ineligible patients with newly diagnosed multiple myeloma: analysis of the phase 3 OCTANS study
2025 · Weijun Fu, Soo-Mee Bang, et al. · Annals of Hematology · 4
PDF
BRD4 inhibition sensitizes glioblastoma to radiotherapy by suppressing super-enhancer-driven COL1A1
2025 · Xichen Fan, Yi Yang, et al. · Oncogene · 3
Works count: 69
Citation count: 351
H-index: 11
I10-index: 13
Year
Topic
Type